Serious Shortage Protocol (SSP) for Lenzetto® (estradiol) 1.53mg/dose transdermal spray – corresponding guidance on endorsement, prescription charges, remuneration and reimbursement plus Q&A.

SSP 026 for Lenzetto® (estradiol) 1.53mg/dose transdermal spray

There are three live SSPs for this product:

- **SSP 026** – where the duration of treatment on the prescription exceeds 3 months and Lenzetto® is in stock this SSP applies.
- **SSP 027** – where the duration of treatment on the prescription is 3 months or less, Lenzetto® is not in stock, and substitution is deemed clinically appropriate.
- **SSP 028** – Where the duration of treatment on the prescription exceeds 3 months, Lenzetto® is not in stock and substitution is deemed clinically appropriate.

1) Endorsement

The contractor must endorse the prescription form or Electronic Reimbursement Endorsement Message (EREM) as per Clause 9, Part II of the Drug Tariff.

**Electronic prescription:**

Where SSP endorsement functionality is available on the dispensing system the contractor must select SSP and input the three-digit reference number, leaving a space between SSP and the reference number, as shown below. The contractor must also select in the system the SSP item that has been supplied.

<table>
<thead>
<tr>
<th>Example</th>
<th>Endorsement Option</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription for Lenzetto® (estradiol) 1.53mg/dose transdermal spray</td>
<td>SSP 026</td>
</tr>
<tr>
<td>Pharmacy contractor supplies Lenzetto® (estradiol) 1.53mg/dose transdermal spray x REDUCED QUANTITY IN LINE WITH SSP</td>
<td></td>
</tr>
<tr>
<td>Pharmacy contractor selects in system Lenzetto® (estradiol) 1.53mg/dose</td>
<td></td>
</tr>
</tbody>
</table>
Non-electronic prescription form:

<table>
<thead>
<tr>
<th>Example</th>
<th>Endorsement option</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prescription for Lenzetto® (estradiol) 1.53mg/dose transdermal spray</strong> Pharmacy contractor supplies Lenzetto® (estradiol) 1.53mg/dose transdermal spray x REDUCED QUANTITY IN LINE WITH SSP</td>
<td>SSP 026 Pharmacy contractor endorses Lenzetto® (estradiol) 1.53mg/dose transdermal spray x REDUCED QUANTITY IN LINE WITH SSP</td>
</tr>
</tbody>
</table>

2) Prescription charges

For supply in accordance with this SSP 026, no prescription charges will be applicable for Lenzetto® (estradiol) 1.53mg/dose transdermal spray.

In order to ensure prescription charges are reconciled correctly, pharmacy contractors must endorse the correct SSP number.

3) Remuneration

Supply in accordance with this SSP 026 will result in the following fees being paid to the contractor:
- One Single Activity Fee (£1.27)
- One SSP fee (£5.35)

4) Reimbursement

The supplied product in accordance with this SSP 026 will be reimbursed as if it was dispensed against a prescription. In this instance, contractors will be reimbursed the Part VIII A reimbursement price for the quantity supplied for Lenzetto® (estradiol) 1.53mg/dose transdermal spray.

The reimbursement price will account for VAT payment.

**Q&A**

**Will the SSP apply to cross-border prescriptions?**

Yes. Patients from England, Scotland, Wales or Northern Ireland who present their prescriptions for Lenzetto® (estradiol) 1.53mg/dose transdermal spray are eligible to receive a lower quantity under the terms of this SSP 026.
Does the SSP apply to private prescriptions?

Yes. The scope of this SSP 026 applies to valid prescriptions that meets the requirements of the Human Medicine Regulations 2012, so it would cover both NHS and private prescriptions, unless where it stated otherwise on the SSP itself.

Will prescription charges apply under the SSP?

As a supply in accordance with this SSP 026 is for a lower quantity compared to dispensing the prescription, for NHS prescriptions, no prescription charge will be applicable.

For patient’s **EXEMPT** from prescription charges, the exemption should be marked in accordance with the usual procedure. When declaring prescription totals at the end of the month, pharmacists should continue to declare these prescriptions as exempt.

For patient’s that **PAY** for their prescriptions, the pharmacist should mark on the prescription that a charge has been paid, however **NO** charge should be taken. When declaring prescription totals at the end of the month, pharmacists should declare these prescriptions as paid. The NHS Business Services Authority will amend total monthly figures to account for prescriptions covered by this SSP 026. In order for the NHS Business Services Authority to appropriately amend the total monthly figures it is critical that the prescription is correctly endorsed with the SSP number SSP 026.

Can pharmacists use their professional judgement to supply an alternative product to patients?

Supply in accordance with this SSP only allows supply of a three-month quantity when the prescription is for a longer duration of treatment. It does not allow the supply of a different product. However, if the pharmacist does not have supply of Lenzetto® they should consider whether supply in accordance with SSP 028 would be suitable. Or if they think that an alternative product would be suitable for the patient, they should either contact the prescriber to discuss this (with the patient’s consent) or direct the patient back to the prescriber.

How would pharmacists determine a three-month supply?

Where it is not clear from the prescription what constitutes a three-month supply, the pharmacist will need to discuss with the patient *and* use their professional judgment.

What should pharmacists supply if the prescription states less than three months’ supply should be dispensed?
If the prescription states that either three months’ supply or less is to be supplied to the patient, this SSP 026 does not apply. The pharmacist should dispense the medication in accordance with the prescription and prescription charges are payable.

**Can pharmacists supply more than three months’ supply?**

No, in accordance with this SSP 026, pharmacists will only be able to dispense three months’ supply for Lenzetto® (estradiol) 1.53mg/dose transdermal spray. Patients should be made aware that under the terms of this SSP 026, the prescription will be deemed complete, and no further supply can be made from the same prescription above the three-month quantity.

**What can a pharmacist do if the patient does not consent to receiving the medicine supplied in accordance with this SSP?**

Where a patient does not consent to receive a lower quantity in accordance with this SSP 026, the pharmacists should use their professional judgement to determine if other courses of action are appropriate whilst taking into consideration wider supply issues. For example, pharmacists in England must consider under their NHS terms of service if it is “reasonable and appropriate” to supply in accordance with this SSP 026 or another SSP, such as SSP 027 or SSP 028. If the pharmacist concludes that it is not reasonable or appropriate to supply the medication in accordance with any of the SSPs, the pharmacist must consider if they can dispense the prescription in the usual way ‘in a reasonable timescale’. If they can, the ordinary obligation to dispense in accordance with the prescription applies. If they cannot, because the pharmacist has insufficient supply to fulfil the prescribed quantity within a reasonable timescale, the pharmacist may return the prescription, but if they do so, the pharmacist must provide the patient with appropriate advice about going back to the prescriber.

In the event that the pharmacist concludes that it is reasonable and appropriate to dispense in accordance with the SSP, but the patient persists in refusing to accept the option of the lesser quantity, the pharmacist may advise the patient that they will dispense in accordance with the SSP or not at all, if that is in accordance with their professional judgement.

The patient retains the right to either accept the professional decision of the pharmacist or to ask for their prescription to be returned to them.

**Does the SSP apply to other Hormone Replacement Therapies?**

No, this SSP 026 only applies to Lenzetto® (estradiol) 1.53mg/dose transdermal spray.